title: Low activation of Insulin-like Growth Factor 1-Receptor (IGF1R) is associated with local recurrence in early breast carcinoma.
abstract: Background The predictive value of IGF1R on local recurrence in invasive breast carcinoma (BC) is not well known. Methods In a series of 197 lymph-node negative BC patients treated with breast-conserving surgery and radiation therapy, we performed immunohistochemistry for alpha-IGF1R, beta-IGF1R (phosphorylated/active form) and Estrogen/Progesterone receptors. We further evaluated the IGF1R mRNA expression by quantitative RT-PCR and IGF1R mutations by direct DNA sequencing (exons 19 and 21) in 85 primary BC (42 control cases, 31 with local recurrence and 12 with distant metastasis) and in 31 local recurrences. Unconditional logistic regression analyses were performed to identify risk factors for recurrence. Results Local recurrences were associated with high-grade tumors, PR-negative and low active-IGF1R, which emerged as independent breast relapse predictors by multivariate analysis. Conclusion Patients with early BC treated with lumpectomy and radiation who have low-grade tumors and favorable markers (increased content of active IGF1R and PR-positive) have a low risk of local recurrence. Therefore, do not benefit from a boost dose on the surgical scar.
authors.affiliation: Research Unit, Hospital General Universitari d'Alacant, c/ Pintor Baeza s/n, 03010 Alacant, Spain. peiro_glo@gva.es
authors.forename: Gloria
authors.initials: G
authors.lastname: Peiró
authors.forename: Susana
authors.initials: S
authors.lastname: Benlloch
authors.forename: Laura
authors.initials: L
authors.lastname: Sánchez-Tejada
authors.forename: Encarna
authors.initials: E
authors.lastname: Adrover
authors.forename: Enrique
authors.initials: E
authors.lastname: Lerma
authors.forename: Francisca M
authors.initials: FM
authors.lastname: Peiró
authors.forename: José
authors.initials: J
authors.lastname: Sánchez-Payá
authors.forename: F Ignacio
authors.initials: FI
authors.lastname: Aranda
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D012333:RNA, Messenger / Q000032:analysis; D011878:Radiotherapy; D017526:Receptor, IGF Type 1 / Q000235:genetics / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D046888:Tissue Array Analysis
chemical_list: D012333:RNA, Messenger; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D017526:Receptor, IGF Type 1